CY1119828T1 - Φαρμακευτικες συνθεσεις που περιεχουν εκλεκτικους συνδετες υποδοχεα ντοπαμινης και μεθοδοι θεραπειας χρησιμοποιωντας εκλεκτικους συνδετες υποδοχεα ντοπαμινης - Google Patents
Φαρμακευτικες συνθεσεις που περιεχουν εκλεκτικους συνδετες υποδοχεα ντοπαμινης και μεθοδοι θεραπειας χρησιμοποιωντας εκλεκτικους συνδετες υποδοχεα ντοπαμινηςInfo
- Publication number
- CY1119828T1 CY1119828T1 CY20171101293T CY171101293T CY1119828T1 CY 1119828 T1 CY1119828 T1 CY 1119828T1 CY 20171101293 T CY20171101293 T CY 20171101293T CY 171101293 T CY171101293 T CY 171101293T CY 1119828 T1 CY1119828 T1 CY 1119828T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methods
- pharmaceutical compositions
- compositions containing
- embodimental
- dopamin
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229960003638 dopamine Drugs 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 4
- 102000015554 Dopamine receptor Human genes 0.000 abstract 2
- 108050004812 Dopamine receptor Proteins 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000028683 bipolar I disease Diseases 0.000 abstract 1
- 208000025307 bipolar depression Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 abstract 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95369407P | 2007-08-03 | 2007-08-03 | |
| PCT/US2008/072066 WO2009020897A1 (en) | 2007-08-03 | 2008-08-04 | Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119828T1 true CY1119828T1 (el) | 2018-06-27 |
Family
ID=40338740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171101293T CY1119828T1 (el) | 2007-08-03 | 2017-12-07 | Φαρμακευτικες συνθεσεις που περιεχουν εκλεκτικους συνδετες υποδοχεα ντοπαμινης και μεθοδοι θεραπειας χρησιμοποιωντας εκλεκτικους συνδετες υποδοχεα ντοπαμινης |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20090036468A1 (https=) |
| EP (1) | EP2185155B1 (https=) |
| JP (1) | JP5460594B2 (https=) |
| KR (1) | KR101612563B1 (https=) |
| CN (1) | CN101815519B (https=) |
| AU (1) | AU2008283989B2 (https=) |
| CA (1) | CA2695519A1 (https=) |
| CY (1) | CY1119828T1 (https=) |
| DK (1) | DK2185155T3 (https=) |
| EA (1) | EA018064B1 (https=) |
| ES (1) | ES2653852T3 (https=) |
| HR (1) | HRP20171908T1 (https=) |
| HU (1) | HUE036004T2 (https=) |
| LT (1) | LT2185155T (https=) |
| MY (1) | MY157192A (https=) |
| NO (1) | NO2185155T3 (https=) |
| PL (1) | PL2185155T3 (https=) |
| PT (1) | PT2185155T (https=) |
| SI (1) | SI2185155T1 (https=) |
| WO (1) | WO2009020897A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2317852T3 (pl) | 2008-07-16 | 2015-05-29 | Richter Gedeon Nyrt | Preparaty farmaceutyczne zawierające ligandy receptora dopaminy |
| US20110117214A1 (en) * | 2009-11-16 | 2011-05-19 | Auspex Pharmaceuticals, Inc. | Cyclohexyl urea modulators of d2 receptors and/or d3 receptors |
| US8691836B2 (en) * | 2010-06-18 | 2014-04-08 | Altos Therapeutics, LLC | D2 antagonists, methods of synthesis and methods of use |
| US8912197B2 (en) | 2012-08-20 | 2014-12-16 | Forest Laboratories Holdings Ltd. | Crystalline form of carbamoyl-cyclohexane derivatives |
| US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
| HUP1700253A1 (hu) * | 2017-06-13 | 2019-01-28 | Richter Gedeon Nyrt | Szilárd orális gyógyszerkészítmények |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
| HU231500B1 (hu) * | 2019-04-10 | 2024-04-28 | Richter Gedeon Nyrt | Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére |
| KR20220009954A (ko) | 2019-04-17 | 2022-01-25 | 컴퍼스 패쓰파인더 리미티드 | 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법 |
| MX2024005256A (es) * | 2021-10-28 | 2024-09-06 | Abbvie Inc | Tratamiento del trastorno depresivo mayor. |
| KR20240122455A (ko) * | 2021-12-13 | 2024-08-12 | 컴퍼스 패쓰파인더 리미티드 | 치료-저항성 우울증의 치료에서 사용하기 위한 실로사이빈 및 보조적 세로토닌 재흡수 저해제 |
| IL315074A (en) | 2022-03-17 | 2024-10-01 | Mapi Pharma Ltd | Storage systems containing cryprazine or its salts |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8814057D0 (en) * | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| US6960577B2 (en) * | 1998-05-22 | 2005-11-01 | Eli Lilly And Company | Combination therapy for treatment of refractory depression |
| US6556540B1 (en) * | 1998-05-29 | 2003-04-29 | Paradyne Corporation | System and method for non-intrusive measurement of service quality in a communications network |
| TR200401456T1 (tr) * | 1999-10-25 | 2005-04-21 | H. Lundbeck A/S | Sitalopram hazırlanması için yöntem. |
| UA77650C2 (en) * | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
| EA200301195A1 (ru) * | 2001-05-01 | 2004-04-29 | Х. Лундбекк А/С | Применение энантиомерно чистого эсциталопрама |
| US7030122B2 (en) * | 2002-04-12 | 2006-04-18 | Sepracor Inc. | 1,4-disubstituted piperazine ligands for neurotransmitter receptors |
| WO2004000326A1 (en) * | 2002-06-20 | 2003-12-31 | H. Lundbeck A/S | Combination therapy wherein a serotonin reuptake inhibitor is used |
| HU227534B1 (en) * | 2003-08-04 | 2011-08-29 | Richter Gedeon Nyrt | (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them |
| US20070042014A1 (en) * | 2003-09-04 | 2007-02-22 | H. Lundbeck A/S | Combination of a serotonin reuptake inhibitor and loxapine |
| HUP0500170A3 (en) * | 2005-02-03 | 2007-11-28 | Richter Gedeon Nyrt | Piperazine derivatives, process for producing them and pharmaceutical compositions containing them |
| TW200812993A (en) * | 2006-05-02 | 2008-03-16 | Lundbeck & Co As H | New uses of escitalopram |
| HU230748B1 (hu) * | 2007-05-11 | 2018-02-28 | Richter Gedeon Nyrt | Új piperazin só és előállítási eljárása |
-
2008
- 2008-08-04 CN CN2008801062563A patent/CN101815519B/zh active Active
- 2008-08-04 JP JP2010520238A patent/JP5460594B2/ja active Active
- 2008-08-04 ES ES08782602.0T patent/ES2653852T3/es active Active
- 2008-08-04 CA CA2695519A patent/CA2695519A1/en not_active Abandoned
- 2008-08-04 PT PT87826020T patent/PT2185155T/pt unknown
- 2008-08-04 DK DK08782602.0T patent/DK2185155T3/en active
- 2008-08-04 EA EA201000280A patent/EA018064B1/ru unknown
- 2008-08-04 PL PL08782602T patent/PL2185155T3/pl unknown
- 2008-08-04 LT LTEP08782602.0T patent/LT2185155T/lt unknown
- 2008-08-04 HR HRP20171908TT patent/HRP20171908T1/hr unknown
- 2008-08-04 AU AU2008283989A patent/AU2008283989B2/en active Active
- 2008-08-04 EP EP08782602.0A patent/EP2185155B1/en active Active
- 2008-08-04 KR KR1020107004638A patent/KR101612563B1/ko active Active
- 2008-08-04 SI SI200831900T patent/SI2185155T1/en unknown
- 2008-08-04 MY MYPI2010000523A patent/MY157192A/en unknown
- 2008-08-04 HU HUE08782602A patent/HUE036004T2/hu unknown
- 2008-08-04 US US12/185,211 patent/US20090036468A1/en not_active Abandoned
- 2008-08-04 NO NO08782602A patent/NO2185155T3/no unknown
- 2008-08-04 WO PCT/US2008/072066 patent/WO2009020897A1/en not_active Ceased
-
2010
- 2010-09-27 US US12/890,752 patent/US20110015208A1/en not_active Abandoned
-
2011
- 2011-10-10 US US13/269,928 patent/US20120028991A1/en not_active Abandoned
-
2017
- 2017-12-07 CY CY20171101293T patent/CY1119828T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201000280A1 (ru) | 2010-08-30 |
| LT2185155T (lt) | 2017-12-11 |
| HK1144784A1 (en) | 2011-03-11 |
| WO2009020897A1 (en) | 2009-02-12 |
| PT2185155T (pt) | 2018-01-04 |
| CA2695519A1 (en) | 2009-02-12 |
| EP2185155A1 (en) | 2010-05-19 |
| HUE036004T2 (hu) | 2018-06-28 |
| US20120028991A1 (en) | 2012-02-02 |
| JP2010535790A (ja) | 2010-11-25 |
| SI2185155T1 (en) | 2018-02-28 |
| MY157192A (en) | 2016-05-13 |
| US20090036468A1 (en) | 2009-02-05 |
| KR20100059830A (ko) | 2010-06-04 |
| PL2185155T3 (pl) | 2018-03-30 |
| AU2008283989B2 (en) | 2013-12-05 |
| EA018064B1 (ru) | 2013-05-30 |
| CN101815519B (zh) | 2013-08-21 |
| KR101612563B1 (ko) | 2016-04-14 |
| AU2008283989A1 (en) | 2009-02-12 |
| HRP20171908T1 (hr) | 2018-01-26 |
| EP2185155A4 (en) | 2012-04-25 |
| NO2185155T3 (https=) | 2018-03-03 |
| US20110015208A1 (en) | 2011-01-20 |
| EP2185155B1 (en) | 2017-10-04 |
| JP5460594B2 (ja) | 2014-04-02 |
| ES2653852T3 (es) | 2018-02-09 |
| CN101815519A (zh) | 2010-08-25 |
| DK2185155T3 (en) | 2018-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119828T1 (el) | Φαρμακευτικες συνθεσεις που περιεχουν εκλεκτικους συνδετες υποδοχεα ντοπαμινης και μεθοδοι θεραπειας χρησιμοποιωντας εκλεκτικους συνδετες υποδοχεα ντοπαμινης | |
| EA201101009A1 (ru) | АНТАГОНИСТЫ C5aR | |
| CY1124311T1 (el) | Παρεμποδιστες dna-pk | |
| ECSP10010439A (es) | Antagonistas n,n-disustituidos de aminoalquilbifenilo de receptores d2 de prostaglandina | |
| CY1125025T1 (el) | 2-φορμυλ-3-υδροξυφαινυλοξυμεθυλ ενωσεις ικανες ρυθμισης αιμοσφαιρινης | |
| EA201100133A1 (ru) | Антагонисты рецепторов простагландина d | |
| CL2011003147A1 (es) | Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer. | |
| CY1113386T1 (el) | Αναστολεις πρωτεασωματος | |
| EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| EA201490420A1 (ru) | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С α-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ | |
| CY1112552T1 (el) | Υδροξυμεθυλο πυρρολιδινες ως αγωνιστες β3 αδρενεργικου υποδοχεα | |
| EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| CY1111927T1 (el) | Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων | |
| EA200970967A1 (ru) | Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip) | |
| EA201491161A1 (ru) | Фторированные модуляторы рецепторов эстрогенов и их применение | |
| EA201071245A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс | |
| NO20084007L (no) | Spirokondenserte piperidiner som modulatorer av muskarinreseptorer | |
| EA201171063A1 (ru) | Фармацевтические составы олмесартана | |
| CY1117696T1 (el) | ΝΕΑ ΠΑΡΑΓΩΓΑ ΚΥΚΛΟΕΞΥΛΑΜΙΝΗΣ ΜΕ ΔΡΑΣΕΙΣ β2 ΑΔΡΕΝΕΡΓΙΚΟΥ ΑΓΩΝΙΣΤΗ ΚΑΙ Μ3 ΜΟΥΣΚΑΡΙΝΙΚΟΥ ΑΝΤΑΓΩΝΙΣΤΗ | |
| EA201400969A1 (ru) | Новые терапевтические подходы для лечения болезни паркинсона | |
| NI200700260A (es) | Antagonistas de npy, preparación y usos. | |
| EA201070327A1 (ru) | Катехоламиновые производные и их пролекарства | |
| EA201100921A1 (ru) | Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ | |
| CY1119047T1 (el) | Υποκατεστημενα βενζαμιδια με δραστικοτητα εναντι υποδοχεων ερ4 | |
| EA201170356A1 (ru) | Полиморфные и аморфные формы лакозамида и аморфные композиции |